Recombinant human erythropoietin (rhEPO) treatment of hemodialyzed (HD) patients normalizes the altered phenotype of CD4 + lymphocytes and restores the balance of Th1/Th2 cytokines. We decided to test how the presence of rhEPO in cell culture modulates cytokine production of CD4 + lymphocytes in HD patients with stable hemoglobin level and expression of activation antigens of stimulated CD4 + lymphocytes similar to those observed in healthy individuals. We also tested whether the presence of rhEPO in cell culture protects stimulated CD4 + lymphocytes of HD patients from apoptosis. Peripheral blood mononuclear cells (PBMC) of HD patients were stimulated with an immobilized anti-CD3 antibody with or without addition of rhEPO. The percentage of apoptotic CD4 + lymphocytes and the level of Th1/Th2 cytokines in culture supernatants were measured with flow cytometry. HD patients showed a decrease in the percentage of apoptotic CD4 + cells after stimulation with the anti-CD3 antibody combined with rhEPO. The level of IFN-γ and IL-10 was increased while the level of TNF-α was decreased in the presence of rhEPO in cell culture from HD patients. These results confirm the role of rhEPO signaling in T lymphocytes of HD patients. © Springer Science+Business Media New York 2012.
CITATION STYLE
Lisowska, K. A., Dębska-Ślizień, A., Jasiulewicz, A., Daca, A., Bryl, E., & Witkowski, J. M. (2013). The influence of recombinant human erythropoietin on apoptosis and cytokine production of CD4 + lymphocytes from hemodialyzed patients. Journal of Clinical Immunology, 33(3), 661–665. https://doi.org/10.1007/s10875-012-9835-4
Mendeley helps you to discover research relevant for your work.